Aastrom builds on stem cell success in heart failure

Aastrom Bioscience's stem cell treatment ixmyelocel-T has improved heart function in a Phase IIa study in patients with heart failure due to dilated cardiomyopathy.

Aastrom Bioscience's stem cell treatment ixmyelocel-T has improved heart function in a Phase IIa study in patients with heart failure due to dilated cardiomyopathy.

The Phase IIa study presented this week at a late-breaking clinical trials session at the SCAI 2012 meeting in Las...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapy Areas